Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06876714 · ClinicalTrials.gov registry record · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
A Phase 3 study of Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage I Breast Cancer AJCC v8, sponsored by Alliance for Clinical Trials in Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,524
- Enrollment target
- 20
- Study locations
NCT06876714 is a Phase 3 study of Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage I Breast Cancer AJCC v8 that is actively recruiting participants, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 1,524 participants, above the 335-participant average among 73 other Anatomic Stage II Breast Cancer AJCC v8 trials with a reported enrollment target (355% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06876714, a Phase 3 study of Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage I Breast Cancer AJCC v8, is actively recruiting participants, sponsored by Alliance for Clinical Trials in Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,524 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Conditions Studied
Interventions
- PROCEDURE Echocardiography
- PROCEDURE Multigated Acquisition Scan
- PROCEDURE Mammography
- BIOLOGICAL Trastuzumab (Herceptin)
- BIOLOGICAL Pertuzumab
Study Locations (20)
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- Mercy Cancer Center - Carmichael - Carmichael
- Mercy San Juan Medical Center - Carmichael
- Enloe Medical Center - Chico
- Kaiser Permanente Dublin - Dublin
- Mercy Cancer Center - Elk Grove - Elk Grove
- Kaiser Permanente-Fremont - Fremont
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- UC San Diego Moores Cancer Center - La Jolla
- Fremont - Rideout Cancer Center - Marysville
- Mercy Cancer Center - Merced
- Kaiser Permanente- Modesto MOB II - Modesto
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Mercy Cancer Center - Rocklin - Rocklin
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CARTI Cancer Center - Little Rock
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,524 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2037-03-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06876714
The ClinicalTrials.gov registry entry for NCT06876714 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,524 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 335-participant average among 73 other Anatomic Stage II Breast Cancer AJCC v8 trials with a reported enrollment target (355% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Anatomic Stage II Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Echocardiography is the first listed.
NCT06876714 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arkansas, Arizona.
Frequently Asked Questions
What is clinical trial NCT06876714 about?
NCT06876714 is a clinical study titled "ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab". This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherap...
What is the current status of trial NCT06876714?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,524 participants. The study started on 2025-09-17. Estimated completion is 2037-03-13.
What conditions does trial NCT06876714 study?
This clinical trial studies the following conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Early Stage Breast Carcinoma.
What interventions are being tested in trial NCT06876714?
The interventions under investigation include: Echocardiography (PROCEDURE), Multigated Acquisition Scan (PROCEDURE), Mammography (PROCEDURE), Trastuzumab (Herceptin) (BIOLOGICAL), Pertuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06876714?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06876714 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anatomic Stage II Breast Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
RECRUITING · Phase 3
-
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
RECRUITING · Phase 3
-
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
RECRUITING · Phase 3
-
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
RECRUITING · Phase 3
-
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Anatomic Stage II Breast Cancer AJCC v8
All registered trials for this condition
Anatomic Stage I Breast Cancer AJCC v8
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.